# Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings

> **NCT03619798** · — · UNKNOWN · sponsor: **Silver Lake Research Corporation** · enrollment: 600 (estimated)

## Conditions studied

- Diagnoses Disease

## Interventions

- **DEVICE:** HemoTypeSC

## Key facts

- **NCT ID:** NCT03619798
- **Lead sponsor:** Silver Lake Research Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-03
- **Primary completion:** 2018-08-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03619798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03619798, "Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03619798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*